Patents by Inventor Gera JELLEMA

Gera JELLEMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
    Patent number: 10280468
    Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 7, 2019
    Assignee: Almac Diagnostics Limited
    Inventors: Denis Paul Harkin, Richard Kennedy, Katherine E. Keating, Andrena McCavigan, Laura A. Hill, Steve Deharo, Timothy Davison, Fionnuala Patterson, Sinead Donegan, Gera Jellema, Charlie Gourley
  • EXPRESSION PROFILING FOR CANCERS TREATED WITH ANTI-ANGIOGENIC THERAPY
    Publication number: 20170088902
    Abstract: The present invention relates to a cancer sub-type. Provided are methods for determining clinical prognosis of a subject with cancer, selecting whether to administer an anti-angiogenic therapeutic agent to a subject with cancer and predicting responsiveness of a subject with cancer to an anti-angiogenic therapeutic agent. The methods are based on assessing from the expression level of biomarkers disclosed herein whether the cancer belongs to the sub-type. Companion methods of treating cancer and agents for use in treating cancer are also provided.
    Type: Application
    Filed: May 28, 2015
    Publication date: March 30, 2017
    Applicant: ALMAC DIAGNOSTICS LIMITED
    Inventors: Denis Paul HARKIN, Richard KENNEDY, Andrena MCCAVIGAN, Katherine KEATING, Laura HILL, Steve DEHARO, Timothy DAVISON, Fionnuala PATTERSON, Sinead DONEGAN, Gera JELLEMA, Charlie GOURLEY
  • MOLECULAR DIAGNOSTIC TEST FOR PREDICTING RESPONSE TO ANTI-ANGIOGENIC DRUGS AND PROGNOSIS OF CANCER
    Publication number: 20170073761
    Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
    Type: Application
    Filed: February 9, 2015
    Publication date: March 16, 2017
    Inventors: Denis Paul HARKIN, Richard KENNEDY, Katherine E. KEATING, Andrena MCCAVIGAN, Laura A. HILL, Steve DEHARO, Timothy DAVISON, Fionnuala PATTERSON, Sinead DONEGAN, Gera JELLEMA, Charlie GOURLEY